Evidence map›Paper›PMID 40821426›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025

Intravenous Ceftaroline in Extremely Premature Neonates With Coagulase-Negative Staphylococci Septicemia: A Report of 2 Cases.

Suzan S Assfour, Fahad A AlMoghaileth, Adli Abdelrahim, Amal K Hassouneh, Sara O Salem, Raneem S Assfour, Thanaa M Khalil, Mountasser M Al-Mouqdad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzan S AssfourClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Fahad A AlMoghailethClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Adli AbdelrahimClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Amal K HassounehClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Sara O SalemClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Raneem S AssfourPharmacy College (RSA), Jordan University of Science and Technology, Irbid, Jordan.
Thanaa M KhalilClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.
Mountasser M Al-MouqdadClinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is one of the primary causes of newborn morbidity and mortality, particularly in preterm infants, and coagulase-negative staphylococci (CoNS) is a major cause of bacterial infections in the neonatal intensive care unit (NICU). The treatment of late-onset neonatal staphylococcal sepsis is challenging owing to increased minimum inhibitory concentrations and the potential side effects of vancomycin. Herein, we describe 2 cases of extremely preterm newborns treated with intravenous (IV) ceftaroline (6 mg/kg/dose every 8 hours) for late-onset neonatal staphylococcal sepsis. Both cases were diagnosed with bacteremia and treated with ceftaroline. However, one of the patients died, most likely from sepsis or other factors, including chronic lung illness and prematurity, despite sterile blood cultures after starting the ceftaroline treatment. Large-scale randomized studies are required to examine the optimal dosing, safety, and effectiveness of IV ceftaroline for sepsis caused by CoNS in neonates.

Indexed as

bacteremiaceftarolinecoagulase-negative staphylococcineonatal intensive care unitpremature neonatessepsis

Identifiers

PMID40821426
PMCPMC12351489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.